{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"}],"units":"Participants"}],"description":"Partial Response:\n\n* 50% reduction in the level of serum monoclonal protein for at least two determinations six weeks apart.\n* If present, reduction in 24-hour urinary light chain excretion by either, greater than or equal to 90%, or to \\<200 mg for at least two determinations six weeks apart.\n* 50% reduction in the size of soft tissue plasmacytomas (by clinical or radiographic examination) for at least six weeks.\n* No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response).\n\nComplete Response:\n\n* Disappearance of the original monoclonal protein from the blood and urine on at least two determinations for a minimum of six weeks.\n* \\<5% plasma cells in the bone marrow on at least two determinations for a minimum of six weeks.\n* No increase in the size or number of lytic bone lesions.","groups":[{"description":"Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles.","id":"OG000","title":"Combination Drug Therapy"}],"paramType":"NUMBER","populationDescription":"74 patients were enrolled, but 2 were not evaluable for dose limiting toxicities. 72 patients were included in this analysis.","reportingStatus":"POSTED","timeFrame":"24 weeks (8, 21-day cycles)","title":"The Percentage of Patients That Achieved Partial or Complete Response to Treatment.","type":"SECONDARY","unitOfMeasure":"percentage of patients"}